Recombinant Human 5'-Nucleotidase/CD73 His-tag Avi-tag, CF

CD73, known as ecto-5'-Nucleotidase, converts extracellular nucleoside‑5'‑monophosphates to nucleosides, with AMP as its preferred substrate (1). CD73 is a zinc-dependent, 70 kDa homodimeric enzyme bound to the cell membrane through a glycosyl phophatidylinositol (GPI) anchor. It is composed of an N-terminal domain containing metal binding sites linked via small hinge region to a C-terminal domain containing the substrate binding site and dimerization interface (2). It is expressed by most cell types (3) and is widely expressed in tumor cell lines as well as upregulated in cancerous tissues (4, 5). CD73 is a key enzyme responsible for a rate‑limiting step in the generation of extracellular adenosine. Adenosine is a molecule that signals through activation of purinergic receptors and results in an immunosuppressive role in the tumor microenvironment (4, 6). CD73 has been implicated in many pathological processes including immunomodulation and inflammation (7, 8) tumor growth and metastasis (9-13) making CD73 a potential drug target in cancer. Targeting CD73 inhibition has resulted in numerous reports of favorable antitumor effects (4, 5, 12). Consequently, therapeutic approaches have been tested using knockdown, gene silencing and anti-CD73 therapies (11, 14) as well as small molecule inhibitors (14, 15).

• 5'-Nucleotidase/CD73 Antibodies
• 5'-Nucleotidase/CD73 ELISA Kit
• 5'-Nucleotidase/CD73 Kit
• 5'-Nucleotidase/CD73 Lysate
• 5'-Nucleotidase/CD73 Proteins
• 5'-Nucleotidase/CD73 Proteins and Enzymes
• 5'-Nucleotidase/CD73 ELISA